Biologics Outsourcing Global Market estimated to be worth $106.7 billion by 2030

BANGALORE, India - Oct. 10, 2023 - PRLog -- IQ4I's Report Contains 98 market data tables and 86 figures spread through 705 pages and an exhaustive TOC on "Biologics Outsourcing Global Market", [By Product {(Antibody, Recombinant Proteins, Vaccines, Gene Therapy, Cell Therapy and Others); By Phase (Discovery, Pre-Clinical, Clinical and Commercial); By End-Users (Therapeutics, Diagnostics and Research)}; Biomanufacturing {(By Product (Drug substance and Drug Product), By Process (Mammalian, Microbial and Others); By End-Users (Therapeutics, Diagnostics and Research)}; Cell Line Development {(By Expression system (Mammalian, Microbial and Others); Cell type (CHO, Hybridoma, Mouse myeloma, HEK, BHK, PER.C6 and Others); By Application (Bioproduction, Research and Diagnostics)}; Regional (North America, Europe, Asia Pacific & Rest of the World)]

Biologics are the therapeutic entities composed of sugars, proteins, or nucleic acids and made from natural sources such as human, animal or microorganisms. Biologics also include live attenuated microorganisms (vaccines), allergenic extracts (allergy shots), human cells and tissues (for transplantation), cell and gene therapeutics. Similar to the conventional therapeutics, these drugs help in treating several diseases but are highly specific and more efficient in their disease healing mechanisms. The biologic entities like monoclonal antibodies and recombinant proteins target specific areas during their molecular mechanism of disease curing action.

The biologics outsourcing global market is expected to grow at a double digit CAGR from 2022 to 2030 to reach $106.7 billion by 2030. Major drivers for the biologics outsourcing market include increasing trend of outsourcing among the biopharma companies for gaining an economical access to advanced biologics development and manufacturing capacities and capabilities, advanced bioprocessing capabilities of bioservice providers, increasing approvals and adoption of biologics, increasing R&D spend of biopharma companies and escalating approvals and uptake of biosimilars. Factors like emergence of next generation biotherapeutics, development of personalized and orphan indication therapies and the persistently escalating prevalence of chronic, communicable and autoimmune diseases are expected to boost the market growth. However, increasing focus on in-house biologics manufacturing, huge capital investments for capacity and capability development and compliance with stringent regulatory guidelines are restraining the market.

For more details please visit our website or contact:

Mr. Satish Birudukota,

Website: https://www.iq4i.com

Report link: https://iq4i.com/report-store/

Email: bd@iq4i.com, satish.birudukota@iq4i.com,

Phone: +91-9886722024, 8147030229